Skip to main content
Erschienen in: Journal of Radiation Oncology 3/2016

27.01.2016 | Original Research

Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer

verfasst von: Ikuko Kato, Gregory Dyson, Michael Snyder, Hyeong-Reh Kim, Richard K. Severson

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to investigate whether cancer-specific survival in rectal cancer patients is affected by patient-related factors, conditional on radiation treatment.

Methods

Three hundred fifty-nine invasive rectal cancer patients who consented and provided questionnaire data for a population-based case-control study of colorectal cancer in Metropolitan Detroit were included in this study. Their vital status was ascertained through to the population-based cancer registry. Hazard ratios (HR) for cancer-specific and other deaths and 95 % confidence intervals (CIs) were calculated according to selected patients’ characteristics, stratified by radiation status, using joint Cox proportional hazards models.

Results

A total of 159 patients were found to be deceased after the median follow-up of 9.2 years, and 70 % of them were considered to be cancer specific. Smoking and a history of diabetes were associated with an increased probability of deaths from other causes (HR 3.20, 95 % CI 1.72–5.97 and HR 2.02, 95 % CI 0.98–4.16, respectively), while regular use of non-steroidal anti-inflammatory drugs (NSAIDs) was inversely correlated with cancer-specific mortality (HR 0.50, 95 % CI 0.30–0.81). Furthermore, the associations of smoking and NSAIDs with the two different types of deaths (cancer vs others) significantly varied with radiation status (P values for the interactions = 0.014 for both). In addition, we observed a marginally significantly reduced risk of cancer-specific deaths in the patients who had the relative ketogenic diet (HR 0.49, 95 % 0.23–1.02).

Conclusion

Further research is warranted to confirm these results in order to develop new interventions to improve outcome from radiation treatment.
Literatur
2.
Zurück zum Zitat Glynne-Jones R, Harrison M, Hughes R (2013) Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. Cancer Radiotherapie: journal de la Societe Francaise de Radiotherapie Oncologique 17(7):675–685. doi:10.1016/j.canrad.2013.06.043 CrossRef Glynne-Jones R, Harrison M, Hughes R (2013) Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. Cancer Radiotherapie: journal de la Societe Francaise de Radiotherapie Oncologique 17(7):675–685. doi:10.​1016/​j.​canrad.​2013.​06.​043 CrossRef
4.
Zurück zum Zitat Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B (2005) Improved survival in cancer of the colon and rectum in Sweden. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 31(8):845–853. doi:10.1016/j.ejso.2005.05.002 CrossRef Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B (2005) Improved survival in cancer of the colon and rectum in Sweden. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 31(8):845–853. doi:10.​1016/​j.​ejso.​2005.​05.​002 CrossRef
5.
Zurück zum Zitat Martijn H, Voogd AC, van de Poll-Franse LV, Repelaer van Driel OJ, Rutten HJ, Coebergh JW (2003) Improved survival of patients with rectal cancer since 1980: a population-based study. European Journal of Cancer (Oxford, England: 1990) 39(14):2073–2079CrossRef Martijn H, Voogd AC, van de Poll-Franse LV, Repelaer van Driel OJ, Rutten HJ, Coebergh JW (2003) Improved survival of patients with rectal cancer since 1980: a population-based study. European Journal of Cancer (Oxford, England: 1990) 39(14):2073–2079CrossRef
6.
Zurück zum Zitat Spitale A, Franzetti-Pellanda A, Mazzola P, Richetti A, Mazzuchelli L, Bordoni A (2012) Impact of preoperative radiotherapy on survival in locally advanced rectal cancer: an observational population-based study from the south of Switzerland. European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP) 21(2):139–146. doi:10.1097/CEJ.0b013e32834c9c56 CrossRef Spitale A, Franzetti-Pellanda A, Mazzola P, Richetti A, Mazzuchelli L, Bordoni A (2012) Impact of preoperative radiotherapy on survival in locally advanced rectal cancer: an observational population-based study from the south of Switzerland. European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP) 21(2):139–146. doi:10.​1097/​CEJ.​0b013e32834c9c56​ CrossRef
7.
Zurück zum Zitat Ceelen W, Pattyn P, Boterberg T, Peeters M (2006) Pre-operative combined modality therapy in the management of locally advanced rectal cancer. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 32(3):259–268. doi:10.1016/j.ejso.2005.12.002 CrossRef Ceelen W, Pattyn P, Boterberg T, Peeters M (2006) Pre-operative combined modality therapy in the management of locally advanced rectal cancer. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 32(3):259–268. doi:10.​1016/​j.​ejso.​2005.​12.​002 CrossRef
8.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. doi:10.1056/NEJMoa040694 CrossRefPubMed Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. doi:10.​1056/​NEJMoa040694 CrossRefPubMed
10.
Zurück zum Zitat Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC (2012) Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Color Dis 14(10):e701–e707. doi:10.1111/j.1463-1318.2012.03147.x CrossRef Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC (2012) Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Color Dis 14(10):e701–e707. doi:10.​1111/​j.​1463-1318.​2012.​03147.​x CrossRef
11.
Zurück zum Zitat Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M (2013) C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 33(11):5065–5074PubMed Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M (2013) C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 33(11):5065–5074PubMed
13.
Zurück zum Zitat Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J (2011) Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 71(17):5923–5931. doi:10.1158/0008-5472.can-11-1182 CrossRefPubMed Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J (2011) Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 71(17):5923–5931. doi:10.​1158/​0008-5472.​can-11-1182 CrossRefPubMed
15.
Zurück zum Zitat Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10(9):671–684CrossRefPubMed Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10(9):671–684CrossRefPubMed
18.
Zurück zum Zitat Hedblad B, Engström G, Janzon E, Berglund G, Janzon L (2006) COHb% as a marker of cardiovascular risk in never smokers: results from a population-based cohort study. Scandinavian Journal of Public Health 34(6):609–615. doi:10.1080/14034940600590523 CrossRefPubMed Hedblad B, Engström G, Janzon E, Berglund G, Janzon L (2006) COHb% as a marker of cardiovascular risk in never smokers: results from a population-based cohort study. Scandinavian Journal of Public Health 34(6):609–615. doi:10.​1080/​1403494060059052​3 CrossRefPubMed
19.
Zurück zum Zitat Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, Rangnekar VM (2012) Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer 131(11):2519–2527. doi:10.1002/ijc.27556 CrossRefPubMed Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, Rangnekar VM (2012) Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer 131(11):2519–2527. doi:10.​1002/​ijc.​27556 CrossRefPubMed
22.
Zurück zum Zitat Kato I, Majumdar AP, Land SJ, Barnholtz-Sloan JS, Severson RK (2010) Dietary fatty acids, luminal modifiers, and risk of colorectal cancer. International Journal of Cancer Journal International du Cancer 127(4):942–951. doi:10.1002/ijc.25103 PubMedPubMedCentral Kato I, Majumdar AP, Land SJ, Barnholtz-Sloan JS, Severson RK (2010) Dietary fatty acids, luminal modifiers, and risk of colorectal cancer. International Journal of Cancer Journal International du Cancer 127(4):942–951. doi:10.​1002/​ijc.​25103 PubMedPubMedCentral
23.
Zurück zum Zitat Willett W, Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 124(1):17–27PubMed Willett W, Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 124(1):17–27PubMed
24.
Zurück zum Zitat Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, Strickler HD, Gunter MJ (2013) A comparison of the polytomous logistic regression and joint Cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer Epidemiology Biomarkers & Prevention 22(2):275–285. doi:10.1158/1055-9965.epi-12-1050 CrossRef Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, Strickler HD, Gunter MJ (2013) A comparison of the polytomous logistic regression and joint Cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer Epidemiology Biomarkers & Prevention 22(2):275–285. doi:10.​1158/​1055-9965.​epi-12-1050 CrossRef
28.
Zurück zum Zitat Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. The Lancet Oncology 10 (11):1033–1034. doi:http://dx.doi.org/10.1016/S1470-2045(09)70326–2 Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. The Lancet Oncology 10 (11):1033–1034. doi:http://​dx.​doi.​org/​10.​1016/​S1470-2045(09)70326–2
29.
Zurück zum Zitat National Center for Chronic Disease P, Health Promotion Office on S, Health (2014) Reports of the Surgeon General. The health consequences of smoking-50 years of progress: a report of the surgeon general. Centers for Disease Control and Prevention (US), Atlanta (GA) National Center for Chronic Disease P, Health Promotion Office on S, Health (2014) Reports of the Surgeon General. The health consequences of smoking-50 years of progress: a report of the surgeon general. Centers for Disease Control and Prevention (US), Atlanta (GA)
30.
Zurück zum Zitat IARC (1997) IARC handbooks of cancer prevention, vol 1. Non-Steroidal Anti-Inflammatory Drugs, IARC, Lyon, France IARC (1997) IARC handbooks of cancer prevention, vol 1. Non-Steroidal Anti-Inflammatory Drugs, IARC, Lyon, France
31.
Zurück zum Zitat Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 13 (5):518–527. doi:http://dx.doi.org/10.1016/S1470-2045(12)70112–2 Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 13 (5):518–527. doi:http://​dx.​doi.​org/​10.​1016/​S1470-2045(12)70112–2
32.
33.
Zurück zum Zitat Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612. doi:10.1016/s0140-6736(11)61720-0 CrossRefPubMed Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612. doi:10.​1016/​s0140-6736(11)61720-0 CrossRefPubMed
34.
Zurück zum Zitat Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591–1601. doi:10.1016/s0140-6736(12)60209-8 CrossRefPubMed Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591–1601. doi:10.​1016/​s0140-6736(12)60209-8 CrossRefPubMed
36.
Zurück zum Zitat Corvo R, Antognoni P, Sanguineti G (2001) Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives. Tumori 87(6):355–363PubMed Corvo R, Antognoni P, Sanguineti G (2001) Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives. Tumori 87(6):355–363PubMed
38.
Zurück zum Zitat Semenza GL (2004) Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5(5):405–406CrossRefPubMed Semenza GL (2004) Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5(5):405–406CrossRefPubMed
40.
Zurück zum Zitat Lu XG, Xing CG, Feng YZ, Chen J, Deng C (2006) Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer 5(5):350–353CrossRefPubMed Lu XG, Xing CG, Feng YZ, Chen J, Deng C (2006) Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer 5(5):350–353CrossRefPubMed
41.
Zurück zum Zitat Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM, Guenther T (2009) Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 100(10):1666–1673. doi:10.1038/sj.bjc.6605026 CrossRefPubMedPubMedCentral Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM, Guenther T (2009) Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 100(10):1666–1673. doi:10.​1038/​sj.​bjc.​6605026 CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Silva P, Slevin NJ, Sloan P, Valentine H, Cresswell J, Ryder D, Price P, Homer JJ, West CML (2008) Prognostic significance of tumor hypoxia inducible factor–1α expression for outcome after radiotherapy in oropharyngeal cancer. International Journal of Radiation Oncology Biology Physics 72 (5):1551–1559. doi:http://dx.doi.org/10.1016/j.ijrobp.2008.07.051 Silva P, Slevin NJ, Sloan P, Valentine H, Cresswell J, Ryder D, Price P, Homer JJ, West CML (2008) Prognostic significance of tumor hypoxia inducible factor–1α expression for outcome after radiotherapy in oropharyngeal cancer. International Journal of Radiation Oncology Biology Physics 72 (5):1551–1559. doi:http://​dx.​doi.​org/​10.​1016/​j.​ijrobp.​2008.​07.​051
48.
Zurück zum Zitat Woolf EC, Scheck AC (2015) The ketogenic diet for the treatment of malignant glioma. Journal of Lipid Research 56(1):5–10. doi:10.1194/jlr.R046797 Woolf EC, Scheck AC (2015) The ketogenic diet for the treatment of malignant glioma. Journal of Lipid Research 56(1):5–10. doi:10.​1194/​jlr.​R046797
49.
Zurück zum Zitat Kato I, Yee CL, Dombi GWK, J. F., Severson RK (2007) Race and other factors associated with differential follow-up in a population-based cancer registry. J Registr Manag 34:129–134 Kato I, Yee CL, Dombi GWK, J. F., Severson RK (2007) Race and other factors associated with differential follow-up in a population-based cancer registry. J Registr Manag 34:129–134
50.
Zurück zum Zitat Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. 1141–1154. doi:10.1214/aos/1176350951 Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. 1141–1154. doi:10.1214/aos/1176350951
Metadaten
Titel
Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer
verfasst von
Ikuko Kato
Gregory Dyson
Michael Snyder
Hyeong-Reh Kim
Richard K. Severson
Publikationsdatum
27.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2016
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-016-0245-8

Weitere Artikel der Ausgabe 3/2016

Journal of Radiation Oncology 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.